Premium
Case series of BRAF ‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy
Author(s) -
Fujimura Taku,
Yoshino Koji,
Kato Hiroshi,
Fujisawa Yasuhiro,
Nakamura Yoshiyuki,
Yamamoto Yuki,
Kunimoto Kayo,
Ito Takamichi,
Matsushita Shigeto,
Maekawa Takeo,
Ohuchi Kentaro,
Amagai Ryo,
Muto Yusuke,
Furudate Sadanori,
Kambayashi Yumi,
Hashimoto Akira,
Aiba Setsuya
Publication year - 2021
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15688
Subject(s) - combination therapy , targeted therapy , medicine , cohort , oncology , melanoma , second line therapy , regimen , adverse effect , first line therapy , incidence (geometry) , chemotherapy , cancer research , cancer , physics , optics
The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF ‐mutated advanced melanoma as second‐line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF ‐mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second‐line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first‐line targeted therapy. In contrast, overall survival and progress‐free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well‐tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second‐line therapy and beyond is comparable with that of first‐line targeted therapy.